Cutaneous Oncology News

A novel imaging approach using artificial intelligence was associated with improved detection of parameters associated with melanoma, according to results presented at the International Conference on Image Analysis and Recognition.

The FDA accepted for review new drug applications that seek the use of the COMBO450 regimen to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to the drugs’ manufacturer.

MADRID — Adjuvant vemurafenib conferred substantial clinical benefit to patients with completely resected stage IIC to stage IIIB BRAF V600-positive melanoma at high risk for recurrence, according to study results presented at the European Society for Medical Oncology Congress.

MADRID — Adjuvant treatment with dabrafenib and trametinib doubled RFS compared with placebo among patients with resected stage III BRAF-mutant melanoma, according to results of the randomized phase 3 COMBI-AD trial presented at the European Society for Medical Oncology Congress.

MADRID — Adjuvant treatment with nivolumab significantly prolonged RFS compared with standard ipilimumab for patients with surgically resected stage III or stage IV melanoma at high risk for recurrence, according to results of the randomized, phase 3 CheckMate 238 trial presented at the European Society for Medical Oncology Congress.

The FDA granted breakthrough therapy designation to cemiplimab for the treatment of adults with metastatic or locally advanced and unresectable cutaneous squamous cell carcinoma, according to the drug’s manufacturer.

The BsmI single-nucleotide polymorphism, along with several demographic factors, predicted nonmelanoma skin cancer risk, according to recent findings.

The FDA granted fast track designation to LN-144 for the treatment of advanced melanoma, according to the drug’s manufacturer.

Nevus-associated melanomas accounted for approximately one-third of all melanomas found in a recent systematic review and meta-analysis.

The FDA granted breakthrough therapy designation to mogamulizumab for the treatment of mycosis fungoides and Sézary syndrome, according to the agent’s manufacturer.